Brief: Sanofi And Regeneron’S Dupixent Approved In The U.S. For Allergic Fungal Rhinosinusitis
24/02/2026 14:33
Feb 24 (Reuters) - Sanofi SA SASY.PA: SANOFI AND REGENERON’S DUPIXENT APPROVED IN THE US AS THE FIRST AND ONLY MEDICINE FOR ALLERGIC FUNGAL RHINOSINUSITIS PHASE 3 STUDY SHOWS DUPIXENT REDUCES NASAL SIGNS AND SYMPTOMS DUPIXENT IS NOW APPROVED IN US TO TREAT NINE DISTINCT DISEASES DRIVEN IN PART BY TYPE 2 INFLAMMATION APPROVAL EXPANDS OUR APPROVED INDICATIONS IN SINO-NASAL DISEASES TO NOW INCLUDE AFRS, ALONGSIDE CHRONIC RHINOSINUSITIS WITH NASAL POLYPS Source text: ID:nGNX7lkHgB Further company coverage: SASY.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com ; +48 58 769 66 00;;))
Recent news on Regeneron Pharmaceuticals
See all newsLilly, Regeneron selected for US program to review new manufacturing plants faster (updated)
FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports
Brief: Eli Lilly, Regeneron Among First Companies Selected For FDA Initiative To Speed Review Of New Manufacturing Facilities - CNBC
Brief: Cemdisiran Regulatory Submissions Accepted For Review By FDA And EMA For The Treatment Of Generalized Myasthenia Gravis (Gmg)
AbbVie sharpens immunology focus with $10.9 billion Apogee deal (updated)